Mouse model for hereditary hemorrhagic telangiectasia has a generalized vascular abnormality

被引:89
|
作者
Torsney, E
Charlton, R
Diamond, AG
Burn, J
Soames, JV
Arthur, HM [1 ]
机构
[1] Newcastle Univ, Int Ctr Life, Inst Human Genet, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England
[2] Freeman Rd Hosp, Newcastle Upon Tyne, Tyne & Wear, England
关键词
vasculature; angiogenesis; hemorrhage; inflammation;
D O I
10.1161/01.CIR.0000058170.92267.00
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Mutations in endoglin or activin like kinase-1, both involved in the endothelial transforming growth factor-beta signaling pathway, cause the autosomal dominant bleeding disorder hereditary hemorrhagic telangiectasia. We and others have reported mouse models for this disease that share the characteristic phenotype of dilated vessels and sporadic hemorrhage. The reasons for the variable phenotype in hereditary hemorrhagic telangiectasia are not understood. Methods and Results-After a detailed immunohistochemical analysis of 129/Ola mice, which are heterozygous for a targeted deletion in the endoglin gene, we observed intrinsic abnormalities in the vascular walls throughout the cutaneous vasculature. Postcapillary venules were dilated, and up to 70% of the vascular wall had no smooth muscle cells. The supporting layers of collagens and elastin were irregular, with thin areas, adding to the fragility of these vessels. A variable hemorrhagic phenotype was observed in which local bleeding is associated not only with fragile vessels but also with regions of inflammation. Conclusions-These findings have relevance to our understanding of the molecular basis of vascular integrity in a wide range of diseases.
引用
收藏
页码:1653 / 1657
页数:5
相关论文
共 50 条
  • [31] VEGFR2 Expression Correlates with Postnatal Development of Brain Arteriovenous Malformations in a Mouse Model of Type I Hereditary Hemorrhagic Telangiectasia
    Han, Chul
    Nguyen, Candice L.
    Scherschinski, Lea
    Schriber, Tyler D.
    Arthur, Helen M.
    Lawton, Michael T.
    Oh, Suk Paul
    BIOMEDICINES, 2023, 11 (12)
  • [32] Intravenous bevacizumab for complications of hereditary hemorrhagic telangiectasia: a review of the literature
    Arizmendez, Natalia P.
    Rudmik, Luke
    Poetker, David M.
    INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY, 2015, 5 (11) : 1042 - 1047
  • [33] Adrenomedullin as a potential biomarker involved in patients with hereditary hemorrhagic telangiectasia
    Iriarte, A.
    Ochoa-Callejero, L.
    Garcia-Sanmartin, J.
    Cerda, P.
    Garrido, P.
    Narro-Iniguez, J.
    Mora-Lujan, J. M.
    Jucgla, A.
    Sanchez-Corral, M. A.
    Cruellas, F.
    Gamundi, E.
    Ribas, J.
    Castellote, J.
    Vinals, F.
    Martinez, A.
    Riera-Mestre, A.
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2021, 88 : 89 - 95
  • [34] Systemic therapy with bevacizumab in patients with hereditary hemorrhagic telangiectasia (HHT)
    Chavan, Ajay
    Schumann-Binarsch, Silke
    Luthe, Lars
    Nickau, Britta
    Elsaesser, Albrecht
    Kuehnel, Thomas
    Geisthoff, Urban
    Koehne, Henning
    VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE, 2013, 42 (02) : 106 - 110
  • [35] Improved Survival Outcomes in Cancer Patients with Hereditary Hemorrhagic Telangiectasia
    Duarte, Christine W.
    Murray, Kimberly
    Lucas, F. Lee
    Fairfield, Kathleen
    Miller, Heather
    Brooks, Peter
    Vary, Calvin P. H.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2014, 23 (01) : 117 - 125
  • [36] Involvement of the transforming growth factor β in the pathogenesis of hereditary hemorrhagic telangiectasia
    Jirillo, E.
    Amati, L.
    Suppressa, P.
    Cirimele, D.
    Guastamacchia, E.
    Covelli, V.
    Tafaro, E.
    Sabba, C.
    CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (10) : 1195 - 1200
  • [37] Aflibercept for Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia: A Case Report
    Villanueva, Bernat
    Iriarte, Adriana
    Torres-Iglesias, Raquel
    Munoz Bolano, Miriam
    Cerda, Pau
    Riera-Mestre, Antoni
    MEDICINA-LITHUANIA, 2023, 59 (09):
  • [38] VEGF neutralization can prevent and normalize arteriovenous malformations in an animal model for hereditary hemorrhagic telangiectasia 2
    Chul Han
    Se-woon Choe
    Yong Hwan Kim
    Abhinav P. Acharya
    Benjamin G. Keselowsky
    Brian S. Sorg
    Young-Jae Lee
    S. Paul Oh
    Angiogenesis, 2014, 17 : 823 - 830
  • [39] PTEN (Phosphatase and Tensin Homolog) Connection in Hereditary Hemorrhagic Telangiectasia 2
    Bischoff, Joyce
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2018, 38 (05) : 984 - 985
  • [40] Decreased Expression of Vascular Endothelial Growth Factor Receptor 1 Contributes to the Pathogenesis of Hereditary Hemorrhagic Telangiectasia Type 2
    Thalgott, Jeremy H.
    Dos-Santos-Luis, Damien
    Hosman, Anna E.
    Martin, Sabrina
    Lamande, Noel
    Bracquart, Diane
    Srun, Samly
    Galaris, Georgios
    de Boer, Hetty C.
    Tual-Chalot, Simon
    Kroon, Steven
    Arthur, Helen M.
    Cao, Yihai
    Snijder, Repke J.
    Disch, Frans
    Mager, Johannes J.
    Rabelink, Ton J.
    Mummery, Christine L.
    Raymond, Karine
    Lebrin, Franck
    CIRCULATION, 2018, 138 (23) : 2698 - 2712